Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies

• Published in: PloS one Vol. 9; no. 4; p. e93437
• Main Authors: Li, Jiaoyuan, Zou, Li, Chen, Wei, Zhu, Beibei, Shen, Na, Ke, Juntao, Lou, Jiao, Song, Ranran, Zhong, Rong, Miao, Xiaoping
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01-04-2014; Public Library of Science (PLoS)
• Subjects: Agaricales; Alcohol use; Anticancer properties; Biology and Life Sciences; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - prevention & control; Cancer; Cancer therapies; Care and treatment; Confidence intervals; Diet; Dietary intake; Education; Environmental protection; Epidemiology; Exercise; Feeding Behavior; Female; Genetic aspects; Health aspects; Health risk assessment; Health risks; Humans; Laboratories; Lifestyles; Medical ethics; Medical prognosis; Medicine and Health Sciences; Menopause; Meta-analysis; Mushrooms; Observational studies; Odds Ratio; Physical Sciences; Post-menopause; Postmenopausal women; Public health; Publication Bias; Research and Analysis Methods; Risk; Risk assessment; Risk factors; Risk reduction; Science; Scientific papers; Search engines; Statuary; Studies; Systematic review; China
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0093437

Epidemiological studies have investigated the potential anticancer effects of mushroom intake. This review aims to clarify the evidence on the association of dietary mushroom intake with breast cancer risk and to quantify its dose-response relationship. Relevant studies were identified by a search of PubMed, Web of Science and Google Scholar up to December 31, 2013. Observational studies with relative risks (RRs) or hazard ratios (HRs) or odd ratios (ORs) and 95% confidence intervals (CIs) of breast cancer for three or more categories of mushroom intake were eligible. The quality of included studies was assessed by using Newcastle-Ottawa Scale. A dose-response meta-analysis was performed by utilizing generalized least squares trend estimation. Eight case-control studies and two cohort studies with a total of 6890 cases were ultimately included. For dose-response analysis, there was no evidence of non-linear association between mushroom consumption and breast cancer risk (P = 0.337) and a 1 g/d increment in mushroom intake conferred an RR of 0.97 (95% CI: 0.96-0.98) for breast cancer risk, with moderate heterogeneity (I(2) = 56.3%, P = 0.015). Besides, available menopause data extracted from included studies were used to evaluate the influence of menopausal statues. The summary RRs of mushroom consumption on breast cancer were 0.96 (95% CI: 0.91-1.00) for premenopausal women and 0.94 (95% CI: 0.91-0.97) for postmenopausal women, respectively. Our findings demonstrated that mushroom intake may be inversely associated with risk of breast cancer, which need to be confirmed with large-scale prospective studies further.